Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas
Felipe F. Casanueva,Mark E. Molitch,Janet A. Schlechte,Roger Abs,Vivien Bonert,Marcello D. Bronstein,Thierry Brue,Paolo Cappabianca,Annamaria Colao,Rudolf Fahlbusch,Hugo L. Fideleff,Moshe Hadani,Paul A. Kelly,David L. Kleinberg,Edward R. Laws,Josef Marek,Maurice F. Scanlon,Luís G. Sobrinho,John Wass,Andrea Giustina +19 more
Reads0
Chats0
TLDR
These guidelines represent the current recommendations on the diagnosis and management of prolactinomas based upon comprehensive analysis and synthesis of all available data.Abstract:
In June 2005, an ad hoc Expert Committee formed by the Pituitary Society convened during the 9th International Pituitary Congress in San Diego, California. Members of this committee consisted of invited international experts in the field, and included endocrinologists and neurosurgeons with recognized expertise in the management of prolactinomas. Discussions were held that included all interested participants to the Congress and resulted in formulation of these guidelines, which represent the current recommendations on the diagnosis and management of prolactinomas based upon comprehensive analysis and synthesis of all available data.read more
Citations
More filters
Journal ArticleDOI
Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline
Shlomo Melmed,Felipe F. Casanueva,Andrew R. Hoffman,David L. Kleinberg,Victor M. Montori,Janet A. Schlechte,John A.H. Wass +6 more
TL;DR: This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system to describe both the strength of recommendations and the quality of evidence for diagnosis and treatment of hyperprolactinemia.
Journal ArticleDOI
Diagnosis and Treatment of Pituitary Adenomas: A Review
TL;DR: Patients with pituitary adenomas should be identified at an early stage so that effective treatment can be implemented and measurement of a late-night salivary cortisol level is the best screening test.
Journal ArticleDOI
Pituitary incidentaloma: an endocrine society clinical practice guideline.
Pamela U. Freda,Albert Beckers,Laurence Katznelson,Mark E. Molitch,Victor M. Montori,Kalmon D. Post,Mary Lee Vance +6 more
TL;DR: Practice guidelines for the endocrine evaluation and treatment of pituitary incidentalomas are presented, including indications for surgery.
Journal ArticleDOI
Hyperprolactinemia and prolactinomas.
TL;DR: Any process interfering with dopamine synthesis, its transport to the pituitary gland, or its action at the level of lactotroph dopamine receptors can cause hyperprolactinemia, and hyper Prolactinomas can have clinical effects not only on the reproductive axis.
Journal ArticleDOI
The incidence rate of pituitary adenomas in western Sweden for the period 2001-2011.
Axel Tjörnstrand,Kerstin Gunnarsson,Max Evert,Erik Holmberg,Oskar Ragnarsson,Thord Rosén,Helena Filipsson Nyström +6 more
TL;DR: This study provides a reliable estimate on the overall incidence of PAs and confirms an increased incidence of TSH-producing PAs compared with studies conducted in the pre-magnetic resonance imaging era.
References
More filters
Journal ArticleDOI
Criteria for cure of acromegaly: a consensus statement.
Andrea Giustina,Ariel L. Barkan,Felipe F. Casanueva,F. Cavagnini,Lawrence A. Frohman,Ken K. Y. Ho,Johannes D. Veldhuis,John A.H. Wass,Klaus von Werder,Shlomo Melmed,Shlomo Melmed +10 more
TL;DR: This statement summarizes the consensus achieved in discussions to develop a consensus defining the criteria for cure of acromegaly.
Journal ArticleDOI
A Comparison of Cabergoline and Bromocriptine in the Treatment of Hyperprolactinemic Amenorrhea
Jonathan Webster,Gabriella Piscitelli,Anna Polli,Carlo Ferrari,Ikram Shah Bin Ismail,Maurice F. Scanlon +5 more
TL;DR: Cabergoline is more effective and better tolerated than bromocriptine in women with hyperprolactinemic amenorrhea and Gastrointestinal symptoms were significantly less frequent, less severe, and shorter-lived in the women treated with cabergoline.
Journal ArticleDOI
Dopamine agonists and pituitary tumor shrinkage
TL;DR: Preliminary evidence suggests that dopamine agonists may restrain the growth of some functionless tumors; most of these tumors, however, can be satisfactorily debulked using transsphenoidal surgery, although the number of tumors studied is small.
Journal ArticleDOI
Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study.
Bruno Vergès,Françoise Boureille,Pierre Goudet,Arnaud Murat,Albert Beckers,Geneviève Sassolas,Patrick Cougard,Béatrice Chambe,Corinne Montvernay,Alain Calender +9 more
TL;DR: Pituitary adenomas occur in 42% of the cases and are characterized by a larger size and a more aggressive presentation than without MEN1, and are significantly more frequent in women than in men.
Journal ArticleDOI
Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients.
Johan Verhelst,Roger Abs,Dominique Maiter,Annick Van den Bruel,Mark Vandeweghe,Brigitte Velkeniers,Jean Mockel,G. Lamberigts,Patrick Petrossians,Peter Coremans,Charles Mahler,Achille Stevenaert,Jan Verlooy,Christian Raftopoulos,Albert Beckers +14 more
TL;DR: The high efficacy and tolerability of cabergoline in the treatment of pathological hyperprolactinemia is confirmed, in a large-scale retrospective study, leaving few patients with unacceptable side effects or inadequate clinical response.